BR112012004237A8 - métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10) - Google Patents

métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10)

Info

Publication number
BR112012004237A8
BR112012004237A8 BR112012004237A BR112012004237A BR112012004237A8 BR 112012004237 A8 BR112012004237 A8 BR 112012004237A8 BR 112012004237 A BR112012004237 A BR 112012004237A BR 112012004237 A BR112012004237 A BR 112012004237A BR 112012004237 A8 BR112012004237 A8 BR 112012004237A8
Authority
BR
Brazil
Prior art keywords
alterator
epimetabolic
coenzyme
methods
treating sarcoma
Prior art date
Application number
BR112012004237A
Other languages
English (en)
Other versions
BR112012004237A2 (pt
Inventor
John Patrick Mccook
Niven Rajin Narain
Rangaprasad Sarangarajan
Original Assignee
Berg Pharma Llc
Cytotech Labs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Pharma Llc, Cytotech Labs Llc filed Critical Berg Pharma Llc
Publication of BR112012004237A2 publication Critical patent/BR112012004237A2/pt
Publication of BR112012004237A8 publication Critical patent/BR112012004237A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
BR112012004237A 2009-08-25 2010-08-25 métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10) BR112012004237A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23684509P 2009-08-25 2009-08-25
PCT/US2010/046711 WO2011031503A2 (en) 2009-08-25 2010-08-25 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)

Publications (2)

Publication Number Publication Date
BR112012004237A2 BR112012004237A2 (pt) 2016-04-05
BR112012004237A8 true BR112012004237A8 (pt) 2016-10-04

Family

ID=43730801

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004237A BR112012004237A8 (pt) 2009-08-25 2010-08-25 métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10)

Country Status (15)

Country Link
US (2) US20110064747A1 (pt)
EP (1) EP2470169A4 (pt)
JP (2) JP6159085B2 (pt)
KR (1) KR101572463B1 (pt)
CN (2) CN102548549A (pt)
AU (2) AU2010292532A1 (pt)
BR (1) BR112012004237A8 (pt)
CA (1) CA2772068C (pt)
CR (1) CR20120120A (pt)
EA (1) EA201270325A1 (pt)
IL (1) IL218306B (pt)
IN (1) IN2012DN01911A (pt)
MX (1) MX2012002208A (pt)
SG (2) SG178547A1 (pt)
WO (1) WO2011031503A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132502A2 (en) 2009-05-11 2010-11-18 Cytotech Labs, Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
JP6194003B2 (ja) 2012-10-09 2017-09-06 ザ プロクター アンド ギャンブル カンパニー 有益剤及びこれを含む組成物の特定又は評価方法
JP6189962B2 (ja) 2012-10-09 2017-08-30 ザ プロクター アンド ギャンブル カンパニー 相乗作用する美容成分の組み合わせを特定する方法
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
US10933032B2 (en) * 2013-04-08 2021-03-02 Berg Llc Methods for the treatment of cancer using coenzyme Q10 combination therapies
EP3730131A1 (en) 2013-09-04 2020-10-28 Berg LLC Methods of treatment of cancer by continuous infusion of coenzyme q10
WO2015195737A1 (en) * 2014-06-17 2015-12-23 Stealth Peptides International, Inc. Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
JP6630717B2 (ja) * 2014-07-07 2020-01-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 組織試料における切断ｓｎａｐ２５の検出方法
CN105044360A (zh) * 2015-07-22 2015-11-11 浙江大学医学院附属邵逸夫医院 Rbp4作为结直肠癌血清标记物的应用及诊断试剂盒
CN106053813A (zh) * 2016-06-25 2016-10-26 林森 一种检测鼻咽癌pdk1表达量的免疫组化试剂盒及其应用
CN106947010B (zh) * 2017-04-06 2018-12-11 哈尔滨工业大学 一种利用光引发raft聚合原位诱导自组装制备蛋白质基纳米粒子的方法
CA3063916A1 (en) * 2017-05-17 2018-11-22 Berg Llc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
CN107226862A (zh) * 2017-05-27 2017-10-03 南京川博生物技术有限公司 特异性人ews‑fli1融合蛋白抗体的制备方法及在制备尤文肉瘤诊断抗体试剂的应用
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
CA3210821A1 (en) * 2021-03-05 2022-09-09 Annette KHALED Chaperonin-containing tcp-1 inhibitors for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040749A2 (en) * 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
WO2003087404A1 (en) * 2002-04-17 2003-10-23 Novartis Ag Methods to predict patient responsiveness to tyrosine kinase inhibitors
JP2006345701A (ja) * 2003-07-01 2006-12-28 Taisho Pharmaceut Co Ltd タキサン類応答性の判別方法
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
KR20170102377A (ko) * 2004-01-22 2017-09-08 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
US20080199855A1 (en) * 2004-05-14 2008-08-21 Monica Nister Identification And Characterization Of A Subset of Glioblastomas Sensitive To Treatment With Imatinib
CA2608751A1 (en) * 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101297046B (zh) * 2005-09-02 2013-01-02 东丽株式会社 用于检测尿路上皮癌的试剂盒及方法
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP1991701A4 (en) * 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING, AND TREATING CANCER
US8030013B2 (en) 2006-04-14 2011-10-04 Mount Sinai School Of Medicine Methods and compositions for the diagnosis for early hepatocellular carcinoma
US8148090B2 (en) * 2007-10-18 2012-04-03 Medical Proteoscope Co., Ltd. Method for prediction of postoperative prognosis and diagnosis kit

Also Published As

Publication number Publication date
IL218306A0 (en) 2012-04-30
AU2010292532A1 (en) 2012-04-05
CN108245497A (zh) 2018-07-06
BR112012004237A2 (pt) 2016-04-05
US20130266557A1 (en) 2013-10-10
CA2772068A1 (en) 2011-03-17
EP2470169A2 (en) 2012-07-04
CR20120120A (es) 2012-07-04
US20110064747A1 (en) 2011-03-17
WO2011031503A2 (en) 2011-03-17
KR20120050495A (ko) 2012-05-18
WO2011031503A3 (en) 2011-07-21
JP2013503175A (ja) 2013-01-31
MX2012002208A (es) 2012-06-12
KR101572463B1 (ko) 2015-11-27
CN102548549A (zh) 2012-07-04
JP6159085B2 (ja) 2017-07-05
IL218306B (en) 2018-05-31
EA201270325A1 (ru) 2012-11-30
SG10201405069QA (en) 2014-10-30
AU2016277749A1 (en) 2017-02-02
IN2012DN01911A (pt) 2015-07-24
EP2470169A4 (en) 2013-03-13
SG178547A1 (en) 2012-03-29
CA2772068C (en) 2017-03-21
JP2016136938A (ja) 2016-08-04

Similar Documents

Publication Publication Date Title
BR112012004237A8 (pt) métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10)
BRPI1010827A2 (pt) métodos para tratamento de doença usando um transferidor epimetabólico (coenzima q10)
BR112012006989A2 (pt) método para usar um dispositivo de entretenimento
BRPI1013219A2 (pt) método para o alvejamento-branqueamento enzimático têxtil
GB201119111D0 (en) Illumination apparatus
RS57130B1 (sr) Postupak za dekoraciju površina
BR112013023553A2 (pt) aparelho, método e módulo de mecanismo de iluminação
BR112014007654A2 (pt) inibidores de lrrk2 quinase macrocíclicos.
PL3412687T3 (pl) Sposoby leczenia dlbcl
BR112013028128A2 (pt) composição de polímero para dispositivos elétricos
BR112013024378A2 (pt) novos derivados de pirimidina
EP2646899A4 (en) SYSTEM FOR INTERNETABLE PRINTING
BRPI0911077A2 (pt) método para tratamento de biomassa
EP2791653A4 (en) PROCESS FOR OPTIMIZED SCATTEROMETRY
EP2681534A4 (en) METHODS, SYSTEMS, AND APPARATUS FOR SAMPLE ILLUMINATION
EP2788701B8 (de) Verfahren zum trocknen von schlamm
BR112013028282A2 (pt) composição de polímero para dispositivos elétricos
BR112014012583A2 (pt) derivados de 2-iodoimidazol
EP2796775A4 (en) OPTICAL PLATE FOR ILLUMINATION, AND LIGHTING APPARATUS USING THE SAME
EE00888U1 (et) Kandeseina asendamise meetod
EP2664845A4 (de) Beleuchtungsvorrichtung
BRPI1008016A2 (pt) método para o tratamento de águas residuais
ZA201405390B (en) Method for illuminating space
EP2929235A4 (en) ANTITACHE SYSTEM FOR COHERENT LIGHTING SYSTEM
BR112014008505A2 (pt) mecanismo de travamento

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BERG PHARMA LLC (US)

B25D Requested change of name of applicant approved

Owner name: BERG LLC (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2476 DE 19-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.